13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001631134
Total reported value
$1.9B
$1.9B
60 檔
46.1%
According to the latest 13F quarterly dataset, Sofinnova Investments, Inc. managed an equity portfolio of $1.9B at the end of Q4 2025, spanning 60 distinct U.S. exchange-listed positions.
Sofinnova Investments, Inc. executed strategic sector rebalancing during Q4 2025, establishing 11 new positions while fully exiting 10 holdings and trimming 19 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NTRA | Natera Inc | Stock-Healthcare | 15.31% | +9.98% | — | |
| 2 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 7.04% | +0.25% | +63.01% | |
| 3 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 6.47% | — | +98.11% | |
| 4 | VERA | Vera Therapeutics Inc | Stock-Other | 6.10% | +1.93% | — | |
| 5 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 3.52% | -1.97% | — | |
| 6 | UTHR | United Therapeutics CORP | Stock-Healthcare | 3.31% | -3.28% | -45.21% | |
| 7 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 3.22% | — | +39.63% | |
| 8 | ABBV | Abbvie Inc | Stock-Healthcare | 3.13% | — | +110.50% | |
| 9 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 3.10% | +0.82% | NEW | |
| 10 | COGT | Cogent Biosciences Inc | Stock-Other | 3.02% | -1.02% | -7.25% | |
| 11 | LLY | Eli Lilly & Co | Stock-Healthcare | 2.86% | — | — | |
| 12 | RAPP | Rapport Therapeutics Inc | Stock-Other | 2.49% | +1.84% | -2.22% | |
| 13 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.38% | -1.15% | EXIT | |
| 14 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 2.32% | — | -14.93% | |
| 15 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.90% | +0.77% | +128.66% | |
| 16 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.79% | -0.62% | — | |
| 17 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.74% | — | -5.41% | |
| 18 | CDTX | Cidara Therapeutics Inc | Stock-Other | 1.72% | — | +232.61% | |
| 19 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.60% | -0.67% | -27.26% | |
| 20 | ✓ | Immatics NV | Stock-Other | 1.56% | +0.56% | +54.21% | |
| 21 | INBX | Inhibrx Biosciences Inc | Stock-Other | 1.55% | +0.44% | +3.31% | |
| 22 | IMNM | Immunome Inc | Stock-Other | 1.50% | +0.47% | +271.17% | |
| 23 | AVBP | Arrivent Biopharma Inc | Stock-Other | 1.47% | +1.56% | — | |
| 24 | GKOS | Glaukos CORP | Stock-Healthcare | 1.40% | — | -7.94% | |
| 25 | IDYA | Ideaya Biosciences Inc | Stock-Other | 1.32% | +0.35% | -4.07% | |
| 26 | BIOA | Bioage Labs Inc | Stock-Other | 1.31% | +1.39% | — | |
| 27 | CELC | Celcuity Inc | Stock-Other | 1.29% | -2.89% | EXIT | |
| 28 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.25% | +0.85% | +9.89% | |
| 29 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.19% | — | — | |
| 30 | SUPN | Supernus Pharmaceuticals Inc | Stock-Healthcare | 1.19% | +0.62% | +46.68% | |
| 31 | INSM | Insmed Inc | Stock-Healthcare | 1.18% | -1.28% | +50.28% | |
| 32 | ALC | Alcon Inc. | Stock-Healthcare | 1.13% | -1.20% | — | |
| 33 | RCUS | Arcus Biosciences Inc | Stock-Other | 1.13% | +0.75% | -10.27% | |
| 34 | DXCM | Dexcom Inc | Stock-Healthcare | 1.08% | -0.94% | EXIT | |
| 35 | PHVS | Pharvaris N.V. | Stock-Other | 0.89% | +0.70% | +0.72% | |
| 36 | NKTR | Nektar Therapeutics | Stock-Other | 0.80% | +0.31% | +270.41% | |
| 37 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.78% | -0.51% | EXIT | |
| 38 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.69% | -0.50% | EXIT | |
| 39 | ANAB | Anaptysbio Inc | Stock-Other | 0.60% | +1.20% | +13.14% | |
| 40 | GEHC | GE Healthcare Technology | Stock-Healthcare | 0.57% | — | +6.48% | |
| 41 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.47% | +0.34% | -15.84% | |
| 42 | EXK | Exact Sciences CORP | Stock-Materials | 0.44% | — | -72.21% | |
| 43 | IRON | Disc Medicine Inc | Stock-Other | 0.38% | +0.36% | +719.08% | |
| 44 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 0.27% | — | — | |
| 45 | MASI* | Masimo CORP | Stock-Other | 0.26% | — | — | |
| 46 | QURE | uniQure N.V. | Stock-Other | 0.18% | — | -81.16% | |
| 47 | NXTC | Nextcure Inc | Stock-Other | 0.14% | -0.07% | — | |
| 48 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.12% | +0.01% | -7.47% | |
| 49 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.12% | -0.67% | EXIT | |
| 50 | EVMN | Evommune Inc | Stock-Other | 0.11% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | AZNN | Astrazeneca Plc-spons Adr | +3% | +98.11% | Add |
| 2 | JAZZ | Jazz Pharmaceuticals plc | +2.8% | +63.01% | Add |
| 3 | NTRA | Natera Inc | +1.7% | — | Unchanged |
| 4 | VERA | Vera Therapeutics Inc | +1.7% | — | Unchanged |
| 5 | CDTX | Cidara Therapeutics Inc | +1.4% | +232.61% | Add |
| 6 | COGT | Cogent Biosciences Inc | +1.4% | -7.25% | Trim |
| 7 | ABBV | Abbvie Inc | +1.2% | +110.50% | Add |
| 8 | DYN | Dyne Therapeutics Inc | +1.2% | +128.66% | Add |
| 9 | IMNM | Immunome Inc | +1.2% | +271.17% | Add |
| 10 | PRAX | Praxis Precision Medicines I | +1.1% | -27.26% | Trim |
| 11 | INBX | Inhibrx Biosciences Inc | +0.7% | +3.31% | Add |
| 12 | VRTX | Vertex Pharmaceuticals Inc | +0.7% | +39.63% | Add |
| 13 | CELC | Celcuity Inc | +0.6% | +18.17% | Add |
| 14 | BIOA | Bioage Labs Inc | +0.6% | — | Unchanged |
| 15 | ✓ | Immatics NV | +0.5% | +54.21% | Add |
| 16 | APGE | Apogee Therapeutics Inc | +0.5% | -5.41% | Trim |
| 17 | NKTR | Nektar Therapeutics | +0.4% | +270.41% | Add |
| 18 | ISRG | Intuitive Surgical Inc | +0.4% | +14.49% | Add |
| 19 | CMPX | Compass Therapeutics Inc | +0.4% | +65.88% | Add |
| 20 | INSM | Insmed Inc | +0.4% | +50.28% | Add |
| 21 | IRON | Disc Medicine Inc | +0.3% | +719.08% | Add |
| 22 | RNAGBP | Avidity Biosciences Inc | +0.2% | -14.93% | Trim |
| 23 | RCUS | Arcus Biosciences Inc | +0.2% | -10.27% | Trim |
| 24 | SUPN | Supernus Pharmaceuticals Inc | +0.2% | +46.68% | Add |
| 25 | ANAB | Anaptysbio Inc | +0.2% | +13.14% | Add |
| 26 | NXTC | Nextcure Inc | +0.1% | — | Unchanged |
| 27 | ✓ | Establishment Labs Holdings In | +0.1% | +162.96% | Add |
| 28 | WVE | Wave Life Sciences Ltd. | +0.1% | -7.47% | Trim |
| 29 | ACAD | Acadia Pharmaceuticals Inc | +0.1% | +144.65% | Add |
| 30 | BBIO | Bridgebio Pharma Inc | 0% | -13.39% | Trim |
| 31 | JBIO | Jade Biosciences Inc | 0% | — | Unchanged |
| 32 | EWTX | Edgewise Therapeutics Inc | 0% | -15.84% | Trim |
| 33 | GKOS | Glaukos CORP | — | -7.94% | Trim |
| 34 | IMA | Imagenebio Inc | — | — | Unchanged |
| 35 | BOLT | Bolt Biotherapeutics Inc | 0% | — | Unchanged |
| 36 | IDYA | Ideaya Biosciences Inc | -0.1% | -4.07% | Trim |
| 37 | GEHC | GE Healthcare Technology | -0.1% | +6.48% | Add |
| 38 | RYTM | Rhythm Pharmaceuticals Inc | -0.1% | +9.89% | Add |
| 39 | PHVS | Pharvaris N.V. | -0.1% | +0.72% | Add |
| 40 | AVBP | Arrivent Biopharma Inc | -0.2% | — | Unchanged |
| 41 | SVRA | Savara Inc | -0.4% | -87.45% | Trim |
| 42 | SLNOEUR | Soleno Therapeutics Inc | -0.6% | -92.53% | Trim |
| 43 | EXK | Exact Sciences CORP | -0.7% | -72.21% | Trim |
| 44 | RAPP | Rapport Therapeutics Inc | -0.7% | -2.22% | Trim |
| 45 | DXCM | Dexcom Inc | -1.8% | -51.49% | Trim |
| 46 | ROIV | Roivant Sciences Ltd. | -1.9% | -76.67% | Trim |
| 47 | AXSM | Axsome Therapeutics Inc | -2.5% | -96.88% | Trim |
| 48 | QURE | uniQure N.V. | -2.8% | -81.16% | Trim |
| 49 | UTHR | United Therapeutics CORP | -3.3% | -45.21% | Trim |
| 50 | GILD | Gilead Sciences Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Sofinnova Investments, Inc. reported a total U.S. public equity portfolio value of $1.9B across 60 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NTRA, JAZZ, AZNN) accounted for 46.1% of total reported equity market value during Q4 2025.
Top New Position Initiated
BMY
市值: $81.6M
Top Position Liquidated / Trimmed
GILD
前期市值: $139.0M
During Q4 2025, Sofinnova Investments, Inc.'s top holdings by market value included NTRA (15.3%)、JAZZ (7.0%)、AZNN (6.5%). The largest single position, NTRA, represented 15.3% of total portfolio value.
In Q4 2025, Sofinnova Investments, Inc. made 62 total portfolio adjustments, initiating 11 new buys, adding to 22 positions, trimming 19 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.